

RESEARCH

Open Access



Required concentration index quantifies effective drug combinations against hepatitis C virus infection

Yusuke Kakizoe^{1,2†}, Yoshiki Koizumi^{3†}, Yukino Ikoma¹, Hirofumi Ohashi^{4,5}, Takaji Wakita⁴, Shingo Iwami^{1,6,7,8*†} and Koichi Watashi^{4,5,6,7,9*†}

Abstract

Successful clinical drug development requires rational design of combination treatments based on preclinical data. Anti-hepatitis C virus (HCV) drugs exhibit significant diversity in antiviral effect. Dose-response assessments can be used to determine parameters profiling the diverse antiviral effect during combination treatment. In the current study, a combined experimental and mathematical approaches were used to compare and score different combinations of anti-HCV treatments. A “required concentration index” was generated and used to rank the antiviral profile of possible double- and triple-drug combinations against HCV genotype 1b and 2a. Rankings varied based on target HCV genotype. Interestingly, multidrug (double and triple) treatment not only augmented antiviral activity, but also reduced genotype-specific efficacy, suggesting another advantage of multidrug treatment. The current study provides a quantitative method for profiling drug combinations against viral genotypes, to better inform clinical drug development.

Keywords: Mathematical model, Dose-response curve, Drug combination, Hepatitis C virus (HCV)

Introduction

Newly approved antiviral drugs rely upon dosage, treatment period, and drug combinations established during clinical trials. Trials require large cohorts of patients, significant cost, extensive time and strict management of ethics and compliance: Different dose regimens, treatment times and drug combinations are evaluated during trials [1, 2]. Additional trials are needed to establish drug efficacy against different viral genotypes [3–6]. Despite the significant effort placed in clinical trials, escalation of dosage, increased treatment period, and combination

therapy, significant improvement in efficacy have not always been realized.

Drug concentrations which achieve 50% virus reduction (IC_{50}), can be used to characterize drug activity. Lower IC_{50} means that antiviral effects are achieved with lower concentrations of drug [7]; however, a lower IC_{50} does not necessarily translate to higher antiviral effect. Antiviral effect depends on the Hill coefficient (m), in addition to IC_{50} . A higher m value exponentially increases antiviral activity at higher doses [8–14]. We have previously shown that m is unique to each anti-hepatitis C virus (HCV) drug, and that augmentation of antiviral activity with escalation of drug dose is quite diverse among the types of anti-HCV drugs [14]. Multidrug treatments also result in diverse effects depending on the drug combination. In-depth profiling of drug antiviral effects can be useful in designing a treatment protocol with maximal antiviral efficacy. Such profiling

* Correspondence: siwami@kyushu-u.org; kwatashi@nih.gov

[†]Yusuke Kakizoe, Yoshiki Koizumi, Shingo Iwami and Koichi Watashi contributed equally to this work.

¹Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan

⁴Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan

Full list of author information is available at the end of the article



© The Author(s). 2021, corrected publication 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

could result in significant savings in clinical trials. To date, antiviral efficacy variances between different anti-HCV drugs and drug combinations has not been characterized in detail.

HCV infection is a leading cause of liver cirrhosis and hepatocellular carcinoma, serious public health problems affecting approximately 170 million people worldwide [15]. Recently, the development of new antiviral drugs known as direct acting antivirals (DAAs), have greatly improved treatment outcomes [16, 17]. Commercial interests restrict the combinations which have entered clinical trials as the combinations are all company specific rather than based on any assessment of what would be the best combination for all available agents. Further evaluation of HCV DAA effects could help identify the “best” available therapy and assist with optimizing combination treatments. A new quantitative method could also support evaluation of next generation anti-HCV treatments that could lead to the eradication of HCV. In the current study, we compare antiviral profiles of different classes of anti-HCV drugs to understand diversity of effects.

We recently developed a cell culture system combined with a mathematical model for quantifying anti-HCV drug efficacy at any concentration and multidrug combination [14]. We systematically evaluated and compared the intrinsic anti-HCV activity of 15 antiviral agents and their combinations against HCV genotype 1b. In the current study, we evaluate intrinsic anti-HCV activity in both genotype 1b and 2a. We create an “effectiveness” ranking for HCV replication inhibition in mono- and multi-drug cultures following exposure to high drug dose ranges. Significant diversity was observed between the antiviral activity profiles of different drugs. Thus, it is necessary to carefully select multidrug combinations to increase drug efficacy. We have demonstrated that the developed ranking index is able to delineate the advantages of past first-in-line anti-HCV treatment choices [14]. Thus, in the current study, we use the combined cell culture plus mathematical modeling approach to quantify efficacy of diverse antiviral drug combinations. This framework could be applied to other diseases requiring multidrug treatment, such as tuberculosis and cancer.

Methods

Anti-HCV effect of each drug against genotype 1b or genotype 2a was evaluated with subgenomic replicon systems. As a genotype 1b model, LucNeo#2 (LN2) cells were employed that carry a dicistronic subgenomic replicon including open reading frames (ORFs) for the firefly luciferase-neomycin phosphotransferase fusion protein (translated by HCV 5′-untranslated region) and the NS3–NS5B region of HCV genotype 1b strain NN (translated by encephalomyocarditis virus (EMCV) internal ribosome entry site) [18]. Huh-7.5.1 cells

transfected with a subgenomic replicon that included the ORFs for the NS3–NS5B region of HCV genotype 2a strain JFH-1 and the firefly luciferase gene (SGR-JFH1/Luc) were used for a genotype 2a model [19]. These cells were seeded at 7×10^3 cells per well and treated with indicated concentrations of various drugs. Following 72 h of incubation, cells were lysed and cellular luciferase activity was measured to evaluate the HCV replication activity with a Luciferase Assay System (Promega) per manufacturer’s protocol [18].


Fourteen anti-HCV drugs were evaluated as single treatments. Eleven of these were direct-acting antivirals (DAAs) of the following classes: NS3/4A protease inhibitors [PIs: telaprevir (TPV), danoprevir (DPV), simeprevir (SMV), and asunaprevir (ASV)], nucleoside NS5B polymerase inhibitor [NI: sofosbuvir (SOF)], non-nucleoside NS5B polymerase inhibitors [NNIs: VX-222 (VX), dasabuvir (DAS), nesbuvir (NSV), and tegobuvir (TGV)], and NS5A inhibitors [NS5AI: daclatasvir (DCV) and ledipasvir (LDV)]. The other 3 drugs tested were host-targeting agents (HTAs) including interferon-alpha ($IFN\alpha$) and cyclophilin inhibitors [Cis: cyclosporin A (CsA) and SCY-635]. For multidrug studies, cells were treated with combinations of two or three drugs prior to evaluation of activity. All anti-HCV agents were purchased or kindly provided as described [14].

Results

Fig. 1a provides a schematic of the combined experimental and mathematical system that we previously developed for quantifying anti-HCV activity of drug(s) [14]. In the previous study 14 anti-HCV agents were evaluated in mono and combination treatments against HCV genotype 1b [14]. In the current study the same 14 drugs (Table 1) were tested against HCV genotype 1b (Fig. 1b) and HCV genotype 2a (Fig. 1c). Antiviral activity results from mono and combination treatments were used to develop a novel ranking index, the “required concentration index” or RCI (see below). Note that 14 anti-HCV agents include 11 direct-acting antivirals (DAAs) including NS3 protease inhibitors [PIs; telaprevir (TPV), danoprevir (DPV), simeprevir (SMV), and asunaprevir (ASV)], a nucleoside NS5B polymerase inhibitor [NI; sofosbuvir (SOF)], non-nucleoside NS5B polymerase inhibitors [NNIs; VX-222 (VX), dasabuvir (DAS), nesbuvir (NSV), and tegobuvir (TGV)], and NS5A inhibitors [NS5AI; daclatasvir (DCV) and ledipasvir (LDV)] and 3 host-targeting agents (HTAs) included interferon-alpha ($IFN\alpha$) and cyclophilin inhibitors [CIs; cyclosporin A (CsA) and SCY-635 (SCY)].

Ranking anti-HCV mono-drug treatments

As shown in Fig. 1b, c, the antiviral profile of drugs against HCV genotypes 1b and 2a vary widely,



suggesting that anti-HCV drugs exhibit strain-dependent effects. The typical dose-response curves of a single antiviral drug can be analyzed using the following hill function [14] (Fig. 1d):

$$f_u = \frac{1}{1 + \left(\frac{D}{IC_{50}}\right)^m}. \quad (1)$$

Here, f_u represents the fraction of infection events unaffected by the drug (i.e., $1 - f_u$ equals the fraction of drug-affected events). D is the drug concentration, IC_{50} is the drug concentration that achieves 50% inhibition of

activity, and m is the slope of the dose-response curve (i.e., Hill coefficient) [14]. Dose-response curves for drugs with higher m values show stronger antiviral activity at the same normalized drug concentration so long as the drug concentration is higher than IC_{50} (Fig. 1d). Least-square regression analysis was used to fit Eq.(1) to dose-response curves (Fig. 1b, c) and estimate IC_{50} and m values. Estimated values for each drug against each HCV genotype are summarized in Table 1. The hill function may not accurately fit the dose-response curve at lower drug concentrations (Fig. 1c, especially for doses lower than IC_{50}). Typical clinical drug

Table 1 Estimated characteristic parameters of the tested antiviral drugs

Drug	Type	Target	Class	IC_{50}		m		RCI_{95}	
				genotype 1b	genotype 2a	genotype 1b	genotype 2a	genotype 1b	genotype 2a
TPV (nM)	DAA	NS3 protease	PI	323.79	–	1.72	–	5.54	–
DPV (nM)	DAA	NS3 protease	PI	1.40	–	0.98	–	20.18	–
SMV (nM)	DAA	NS3 protease	PI	0.45	153.95	1.10	3.10	14.54	2.59
ASV (nM)	DAA	NS3 protease	PI	2.75	665.49	0.97	2.99	20.81	2.68
SOF (nM)	DAA	NS5B polymerase NI	NI	120.48	843.74	1.66	3.02	5.89	2.65
VX (pM)	DAA	NS5B polymerase NNI	NNI	107.58	–	1.81	–	5.08	–
DAS (nM)	DAA	NS5B polymerase NNI	NNI	1.50	7203.98	0.99	0.73	19.57	56.39
NSV (nM)	DAA	NS5B polymerase NNI	NNI	0.25	–	1.19	–	11.87	–
TGV (nM)	DAA	NS5B polymerase NNI	NNI	8.92	–	1.01	–	18.45	–
DCV (nM)	DAA	NS5A	NS5AI	0.10	0.13	1.11	3.68	14.19	2.23
LDV (nM)	DAA	NS5A	NS5AI	0.67	30.80	0.96	6.11	21.48	1.62
IFN α (IU/ml)	HTA	–	IFN	2.56	–	1.43	–	7.84	–
CsA (μ g/m)	HTA	Cyclophilin	CI	0.40	–	1.53	–	6.85	–
SCY (μ M)	HTA	Cyclophilin	CI	0.34	–	1.45	–	7.62	–

concentrations are around 10- to 100-fold of IC_{50} , therefore it is generally possible to quantify effectiveness of anti-HCV drug(s) with this method especially for such a high drug concentration. As discussed in recent publications [8–14], both IC_{50} and m values are needed to accurately estimate antiviral drug potency, though only IC_{50} is widely used in the drug development field. Since estimated values for each drug differ relative to target HCV genotype, it is important to optimize mono and combination therapy against each genotype.

To characterize efficacy of drugs, we calculated a “required concentration index” (RCI) for each anti-HCV drug against genotype 1b and 2a. Assuming $1 - f_u = x$ inhibition of viral replication, the RCI_x represents the critical fold increase of IC_{50} requiring x inhibition of viral replication. Solving Eq.(1) for D/IC_{50} , then RCI_x is represented as follows:

$$RCI_x = \frac{D_x}{IC_{50}} = \left(\frac{1}{f_u} - 1 \right)^{\frac{1}{m}} = \left(\frac{x}{1-x} \right)^{\frac{1}{m}}. \quad (2)$$

Here, D_x is the drug concentration required to suppress x of viral replication. Drugs with small RCI_x values are more efficient inhibitors of HCV replication than drugs with high RCI_x . Interestingly, high m tends to be associated with smaller RCI_x . By substituting estimated IC_{50} and m parameters and setting x to 0.95 in Eq.(2), we calculated the RCI_x required for 95% inhibition of HCV replication (i.e., RCI_{95}). We summarize RCI_{95} values of each drug against genotypes 1b and 2a in Fig. 2a, b, respectively. It should be noted that SOF, a nucleoside-type polymerase inhibitor used as a key agent in current and past DAA combinations, was effective in both genotype 1b and 2a, which is




Fig. 2 Ranking anti-HCV mono drug treatments against genotypes 1b and 2a: The critical dose of antiviral drug (i.e., fold increase of IC_{50}) required to inhibit viral replication by 95%, i.e., RCI_{95} , was calculated for HCV (a) genotype 1b and (b) genotype 2a


consistent with SOF's known clinical pan-genotypic anti-HCV characteristic [20].


Ranking anti-HCV multi-drug treatments

Using the replicon system, the antiviral activity of double- and triple-drug combinations (Fig. 3 & Fig. 4) were investigated using consistent ratios of drug concentrations (i.e., $0.25 \times IC_{50}$, $0.5 \times IC_{50}$, $1 \times IC_{50}$, $2 \times IC_{50}$, and $4 \times IC_{50}$).

Inhibitory activity was evaluated for 43 double drug combinations against HCV genotype 1b, and, 9 double drug combinations against genotype 2a. Results are

shown in Fig. 3a, b, respectively. Here, D_a, D_b, \dots, D_i are defined as the concentration of drug a, b, ..., i and $IC_{50}^a, IC_{50}^b, \dots, IC_{50}^i$ refer to the corresponding IC_{50} . Combined drug concentration in these experiments is described as $D^{com} = (D_a, D_b, \dots, D_i) = (\tilde{D} \times IC_{50}^a, \tilde{D} \times IC_{50}^b, \dots, \tilde{D} \times IC_{50}^i)$, where $\tilde{D} = D_a/IC_{50}^a = D_b/IC_{50}^b = \dots = D_i/IC_{50}^i$ is the constant ratio to IC_{50} of each combined drug (x-axis of dose-response curves). As shown in Fig. 3c, a similar hill function can be fit to dose-response curves of drug combinations [14]:





$$f_u^{com} = \frac{1}{1 + \left(\frac{\tilde{D}}{IC_{50}^{com}}\right)^{m^{com}}} \tag{3}$$

Here, f_u^{com} is the fraction of infection events unaffected by the drug combination, IC_{50}^{com} is the constant ratio that inhibits HCV replication by 50%, and m^{com} is the Hill coefficient [14]. In Table 2, we summarize estimated parameters, IC_{50}^{com} and m^{com} , for double-drug combinations.

Similar to mono treatments, the required concentration index for drug combinations is derived as

$$\begin{aligned} RCI_x &= \tilde{D}_c = IC_{50}^{com} \left(\frac{1}{f_u^{com}} - 1 \right)^{\frac{1}{m^{com}}} \\ &= IC_{50}^{com} \left(\frac{x}{1-x} \right)^{\frac{1}{m^{com}}}, \end{aligned} \tag{4}$$

The RCI_{95} required for 95% inhibition of HCV replication is extrapolated from the point at which the curve intersects $f_u^{com} = 0.05$ (dashed line in Fig. 3c). Note that the critical constant ratio, \tilde{D}_c , satisfying Eq.(4) can be uniquely determined. The RCI_{95} values for double-drug combinations against genotype 1b and 2a are summarized in Fig. 3d, e, respectively. RCI_{95} varies depending on drug combination. For genotype 1b, RCI_{95} ranged from 1.56 to 5.14, for genotype 2a RCI_{95} ranged from 1.05 to 2.28. The drug combination with the best anti-HCV profile against genotype 1b is SMV plus IFN α ; Fig. 3d①. This combination used to be the first-in-line anti-HCV drug prior to the development of DAA treatments [17]. Combinations including a non-DAA are presented as gray bars with black number designations. Combinations with DAA-only double treatments are plotted in light pink to blue and designated with white

Table 2 Estimated characteristic parameters of the antiviral drug combinations

Drug	IC_{50}^{com}		m^{com}		RCl ₉₅	
	genotype 1b	genotype 2a	genotype 1b	genotype 2a	genotype 1b	genotype 2a
ASV&CsA	0.80	–	2.25	–	2.95	–
ASV&DAS	0.61	0.28	1.48	1.94	4.50	1.30
ASV&DCV	0.59	0.27	1.41	1.97	4.79	1.22
ASV&IFNa	0.53	–	1.84	–	2.63	–
ASV&LDV	0.65	0.47	1.43	2.30	5.14	1.63
ASV&SCY	0.88	–	1.97	–	3.91	–
ASV&SOF	0.54	0.24	1.47	1.75	4.01	1.29
ASV&VX	0.77	–	1.78	–	4.04	–
DAS&CsA	0.60	–	2.23	–	2.23	–
DAS&DCV	0.47	0.78	1.75	2.80	2.52	2.24
DAS&IFNa	0.40	–	1.84	–	1.96	–
DAS&LDV	0.54	0.86	1.72	3.41	3.00	2.05
DAS&SCY	0.57	–	1.64	–	3.43	–
DCV&CsA	0.50	–	2.02	–	2.14	–
DCV&IFNa	0.40	–	1.79	–	2.08	–
DCV&SCY	0.53	–	1.75	–	2.86	–
IFNa&CsA	0.67	–	2.67	–	2.02	–
IFNa&SCY	0.59	–	2.14	–	2.33	–
LDV&CsA	0.43	–	1.99	–	1.88	–
LDV&IFNa	0.38	–	1.82	–	1.93	–
LDV&SCY	0.52	–	1.79	–	2.69	–
SMV&CsA	0.23	–	1.20	–	2.70	–
SMV&DAS	0.18	–	1.31	–	1.70	–
SMV&DCV	0.20	–	1.26	–	2.08	–
SMV&IFNa	0.17	–	1.34	–	1.56	–
SMV&LDV	0.14	–	1.14	–	1.92	–
SMV&SCY	0.19	–	1.14	–	2.50	–
SMV&SOF	0.20	–	1.38	–	1.71	–
SMV&VX	0.24	–	1.45	–	1.82	–
SOF&CsA	0.55	–	2.18	–	2.12	–
SOF&DAS	0.34	0.62	1.53	2.25	2.36	2.28
SOF&DCV	0.47	0.27	1.64	2.14	2.86	1.05
SOF&IFNa	0.37	–	1.77	–	1.94	–
SOF&LDV	0.42	0.52	1.52	2.43	2.89	1.76
SOF&SCY	0.50	–	1.80	–	2.56	–
SOF&VX	0.47	–	1.57	–	3.09	–
TPV&IFNa	0.46	–	2.14	–	1.81	–
TPV&SOF	0.64	–	2.37	–	2.23	–
VX&CsA	0.77	–	2.71	–	2.27	–
VX&DCV	0.47	–	1.61	–	2.91	–
VX&IFNa	0.47	–	1.83	–	2.35	–
VX&LDV	0.59	–	1.63	–	3.58	–
VX&SCY	0.76	–	2.05	–	3.20	–

numbers (Fig. 3d). For the DAA-only combinations, one of the most effective treatments against genotype 1b was the combination of SMV and SOF (Fig. 3d③), a primary treatment choice in the early era of DAA-only treatment [16]. A long term first-in-line DAA combination, SOF and LDV (Fig. 3d⑩, e⑥), ranked in the mid-range of efficacy against both genotype 1b and 2a. Most other drug combinations ranked differently against genotype 1b and genotype 2a. ASV plus LDV (Fig. 3d⑬, e⑤) was the least effective DAA-only combination against genotype 1b, but fell in the mid-range for effectiveness against genotype 2a. SOF plus DAS (Fig. 3d⑱, e⑨) ranked in the mid-range against genotype 1b, but ranked lowest against genotype 2a. These trends suggest an overall difference in drug effect depending on the target HCV genotype, and indicate the importance of profiling drugs against each genotype.

Eight triple-DAA treatments were profiled against HCV genotype 1b and 6 triple-combinations were evaluated against genotype 2a (Fig. 4a, b). Triple combination assessments included NS3 protease inhibitor (SMV, ASV) with NS5A inhibitor (DCV, LDV) and NI NS5B polymerase inhibitor (SOF), or NS5A inhibitor with NI NS5B polymerase inhibitor and NNI NS5B polymerase inhibitor (VX, DAS). IC_{50}^{com} and m^{com} for triple-drug combinations are summarized in Table 3. We need to note that our experimental assay can detect the range of $0.005 < f_u^{com} < 0.01$ in Fig. 4a, b, whereas it is difficult to measure $f_u^{com} < 0.005$ in areas of higher drug concentration, reaching to the detection limit of the assay. RCI_{95} values of triple-drug combinations against genotype 1b and 2a are summarized in Fig. 4c, d, respectively. RCI_{95} values ranged from 1.21 to 2.33 for genotype 1b and 0.58 to 0.98 for genotype 2a. Triple combination treatment with SOF, LDV and SMV was most effective against genotype 1b (Fig. 4c①), and least effective against genotype 2a (Fig. 4d⑥). SOF plus DCV and SMV (Fig. 4c②) was also significantly effective against genotype 1b, consistent with the reported clinical

efficacy of this triple combination [21, 22]. These results show the optimal combination of drugs to suppress viral replication in vitro, and shed light on the promising drug combinations for improving clinical outcome.

The correlation in ranking between the required concentration index and clinical data suggest that this method could assist with the search for drugs that achieve an efficient antiviral inhibition with different HCV genotypes.

Discussion

Our study shows that the concentration of drug (calculated as fold of IC_{50}), that achieves 95% virus inhibition (RCI_{95}), highly varied depending on the type of drug and combination with other drugs. RCI_{95} of drugs in mono treatment ranged as much as 4.2 fold in antiviral activity against HCV genotype 1b (Fig. 2a, $RCI_{95} = 5.08-21.4$). This diversity in RCI_{95} indicates the importance of characterizing more than just the IC_{50} of drugs when predicting antiviral efficacy in clinical settings. In double-drug combinations, RCI_{95} values decreased (Fig. 3d, e) compared with mono treatments (Fig. 2a, b), indicating elevated antiviral activity resulted from combination treatment. The RCI_{95} values of DAA-only double combinations ranged from 1.70 (SMV & DAS) to 5.14 (ASV & LDV) in genotype 1b and from 1.05 (SOF & DCV) to 2.28 (SOF & DAS) in genotype 2a. Thus, the diversity in RCI_{95} is different among genotypes. Genotype differences are probably due differences in replication activity and the varied dependency on target [23, 24].

Triple DAA treatments have become the final strategy for improving treatment outcomes, especially with difficult-to-treat HCV. Triple combinations are also used as a means to shorten treatment periods. Understanding the activity of triple DAA combinations is important in advancing towards worldwide eradication of HCV virus [25–28]. Consistent with ongoing clinical trials which show higher treatment efficacy of triple-drug combinations, triple combinations reduced RCI_{95} beyond double-

Table 3 Estimated characteristic parameters of the antiviral drug combinations

Drug	IC_{50}^{com}		m^{com}		RCI_{95}	
	genotype 1b	genotype 2a	genotype 1b	genotype 2a	genotype 1b	genotype 2a
SOF&DCV&VX	0.40	–	1.92	–	1.89	–
SOF&DCV&ASV	0.55	0.13	2.03	2.09	2.33	0.58
SOF&DCV&DAS	0.34	0.20	1.97	2.28	1.52	0.73
SOF&DCV&SMV	0.33	0.16	2.14	2.23	1.31	0.62
SOF&LDV&VX	0.45	–	1.90	–	2.12	–
SOF&LDV&ASV	0.46	0.33	1.88	2.88	2.21	0.95
SOF&LDV&DAS	0.35	0.26	1.88	2.49	1.66	0.90
SOF&LDV&SMV	0.26	0.35	1.90	3.04	1.21	0.98

drug combination levels (Fig. 4c, d). RCI_{95} for triple drug combinations ranged from 1.21 to 2.33 in genotype 1b and from 0.58 to 0.98 in genotype 2a. Interestingly, the RCI_{95} values of selected drugs (SMV, ASV, DCV, LDV, DAS, VX and SOF) were less variable in triple-drug combinations compared with double combinations. RCI_{95} ranged 1.9 fold (1.21 for SOF & LDV & SMV to 2.33 for SOF & DCV & ASV) with triple-drug combinations, 3.0 fold (1.70 for SMV & DAS to 5.14 for ASV & LDV) in double-drug combinations, and 4.2 fold (5.08 for VX to 21.4 for LDV) in single-drug treatment against genotype 1b. These data suggest that multidrug treatments such as triple-drug combinations provide more consistent antiviral effect irrespective of the choice of drugs, yet another advantage of triple combinations.

Conclusion

In an era of rapidly progressing anti-HCV treatments, selection of the “best” combination treatment is critical to establishing the next generation of anti-HCV treatments against difficult-to-treat HCV and eventually eradicating HCV. We have developed an integrated experimental and mathematical method to evaluate the efficacy of anti-HCV drugs against HCV genotype 1b and 2a. The method was used to score mono- and multi-drug treatment regimens against HCV. This scoring could be used to optimize multidrug treatment regimens prior to clinical entry.

Abbreviations

HCV: Hepatitis C virus; DAA: Direct acting antiviral; RCI: Required concentration index; TPV: Telaprevir; DPV: Danoprevir; SMV: Simeprevir; ASV: Asunaprevir; SOF: Sofosbuvir; VX: VX-222; DAS: Dasabuvir; NSV: Nesbuvir; TGV: Tegobuvir; DCV: Daclatasvir; LDV: Ledipasvir; IFN α : Interferon-alpha; CsA: Cyclosporin A; SCY: SCY-635

Acknowledgements

We are grateful to Dr. Kunitada Shimotohno at National Center for Global Health and Medicine for providing LucNeo#2 cells. SCY635 was kindly provided by Scynexis, Inc. We appreciate the editorial assistance provided by Dr. Senko Tsukuda at Department of Virology II, National Institute of Infectious.

Authors' contributions

SI and KW designed the experiments. HO and KW conducted the experiments. YK, YK and YI carried out the computational analyses. SI and KW supervised the project. All authors contributed to the manuscript text. The author(s) read and approved the final manuscript.

Funding

This study was supported in part by Grants-in-Aid for JSPS Scientific Research (KAKENHI) Scientific Research B 18KT0018 (to S.I.), 18H01139 (to S.I.), 16H04845 (to S.I.), 17H04085 (to K.W.), Scientific Research in Innovative Areas 19H04839 (to S.I.), 18H05103 (to S.I.); AMED CREST 19 g1310002 (to S.I.); AMED J-PRIDE 19fm0208006s0103 (to S.I.), 19fm0208014h0003 (to S.I.), 19fm0208019h0103 (to S.I.), 19fm0208019j0003 (to K.W.); AMED Research Program on HIV/AIDS 19fk0410023s0101 (to S.I.); Research Program on Emerging and Re-emerging Infectious Diseases 19fk0108050h0003 (to S.I.); Program for Basic and Clinical Research on Hepatitis 19fk0210036h0502 (to S.I.), 19fk0210036j0002 (to K.W.); Program on the Innovative Development and the Application of New Drugs for Hepatitis B 19fk0310114h0103 (to S.I.), 19fk0310114j0003 (to K.W.), 19fk0310101j1003 (to K.W.), 19fk0310103j0203 (to

K.W.); JST MIRAI (to S.I. and K.W.); JST CREST (to S.I. and K.W.); Mitsui Life Social Welfare Foundation (to S.I. and K.W.); Shin-Nihon of Advanced Medical Research (to S.I.); Suzuken Memorial Foundation (to S.I.); Life Science Foundation of Japan (to S.I.); SECOM Science and Technology Foundation (to S.I.); The Japan Prize Foundation (to S.I.); Toyota Physical and Chemical Research Institute (to S.I.); Fukuoka Financial Group, Inc. (to S.I.); Kyusyu Industrial Advancement Center Gapfund Program (to S.I.); Foundation for the Fusion Of Science and Technology (to S.I.); The Yasuda Medical Foundation (to K.W.); Smoking Research Foundation (to K.W.); Takeda Science Foundation (to K.W.); Mochida Memorial Foundation for Medical and Pharmaceutical Research (to K.W.).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan. ²Present address: Data Science Group, Advanced Technology Division, INTAGE Inc, Tokyo 101-8201, Japan. ³National Center for Global Health and Medicine, Tokyo 162-8655, Japan. ⁴Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan. ⁵Department of Applied Biological Science, Tokyo University of Science, Noda 278-8510, Japan. ⁶Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto 606-8501, Japan. ⁷NEXT-Ganken Program, Japanese Foundation for Cancer Research (JFCR), Tokyo 135-8550, Japan. ⁸Science Groove Inc, Fukuoka, Japan. ⁹Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.

Received: 9 June 2020 Accepted: 10 December 2020

Published online: 09 January 2021

References

- Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. *Gastroenterology*. 2014;146(5):1176–92.
- Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. *Liver Int*. 2014;34(Suppl 1):69–78.
- Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. *N Engl J Med*. 2014; 370(20):1889–98.
- Gane EJ, Hyland RH, Yang Y, Svarovskaia E, Stamm LM, Brainard DM, et al. Efficacy of Ledipasvir plus Sofosbuvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2 infection. *Gastroenterology*. 2017;152(6):1366–71.
- Gane EJ, Hyland RH, An D, Svarovskaia E, Pang PS, Brainard D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. *Gastroenterol*. 2015;149(6): 1454–61.e1.
- Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-Centre, open-label phase 2a cohort study. *Lancet Infect Dis*. 2015;15(9):1049–54.
- Aykul S, Martinez-Hackert E. Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysis. *Anal Biochem*. 2016;508:97–103.
- Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. *Nat Med*. 2008;14(7):762–6.
- Sampah ME, Shen L, Jilek BL, Siliciano RF. Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. *Proc Natl Acad Sci U S A*. 2011;108(18):7613–8.

10. Shen L, Rabi SA, Siliciano RF. A novel method for determining the inhibitory potential of anti-HIV drugs. *Trends Pharmacol Sci.* 2009;30(12):610–6.
11. Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, Lai J, et al. A quantitative basis for antiretroviral therapy for HIV-1 infection. *Nat Med.* 2012;18(3):446–51.
12. Shen L, Rabi SA, Sedaghat AR, Shan L, Lai J, Xing S, et al. A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. *Sci Transl Med.* 2011;3(91):91ra63.
13. Laskey SB, Siliciano RF. A mechanistic theory to explain the efficacy of antiretroviral therapy. *Nat Rev Microbiol.* 2014;12(11):772–80.
14. Koizumi Y, Ohashi H, Nakajima S, Tanaka Y, Wakita T, Perelson AS, et al. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. *Proc Natl Acad Sci U S A.* 2017;114(8):1922–7.
15. Lauer GM, Walker BD. Hepatitis C virus infection. *N Engl J Med.* 2001;345(1):41–52.
16. Pawlotsky JM. Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014. *Gastroenterology.* 2015;148(3):468–79.
17. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-a, non-B hepatitis to hepatitis C virus cure. *J Hepatol.* 2015;62(1 Suppl):S87–99.
18. Goto K, Watashi K, Murata T, Hishiki T, Hijikata M, Shimotohno K. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin a, and NIM811. *Biochem Biophys Res Commun.* 2006;343(3):879–84.
19. Kato T, Date T, Miyamoto M, Sugiyama M, Tanaka Y, Orito E, et al. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. *J Clin Microbiol.* 2005;43(11):5679–84.
20. Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. *N Engl J Med.* 2015;373(27):2599–607.
21. Lau G, Benhamou Y, Chen G, Li J, Shao Q, Ji D, et al. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. *Lancet Gastroenterol Hepatol.* 2016;1(2):97–104.
22. Sulikowski MS, Feld JJ, Lawitz E, Felizarta F, Corregidor AM, Khalid O, et al. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection. *J Viral Hepat.* 2018;25(6):631–9.
23. Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J. Recombinant HCV variants with NSSA from genotypes 1-7 have different sensitivities to an NSSA inhibitor but not interferon-alpha. *Gastroenterology.* 2011;140(3):1032–42.
24. McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor Asunaprevir (BMS-650032). *Antimicrob Agents Chemother.* 2012;56(10):5387–96.
25. Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. *Lancet.* 2015;385(9973):1107–13.
26. Everson GT, Sims KD, Rodriguez-Torres M, Hezode C, Lawitz E, Bourliere M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. *Gastroenterology.* 2014;146(2):420–9.
27. Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Brau N, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. *Jama.* 2015;313(17):1728–35.
28. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. *Jama.* 2015;313(17):1736–44.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

